the nih small research grant program supports small research projects that can be carried out in a short period of time with limited resources. this program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

this funding opportunity announcement does not accept applications proposing clinical trial(s).

the fy20 defense appropriation act provides $15 million to the department of defense orthotics and prosthetics outcomes research program (oporp) to support research on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcement/funding opportunity is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy20 oporp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. pre-application and application deadlines will be available when the program announcements are released. 

oporp supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to service members and veterans with limb loss and/or limb impairment. the intent of this research is to generate clinically useful evidence that will enhance and optimize patient outcomes. applications submitted to the fy20 oporp must address at least one of the following focus areas:

• orthoses or prostheses form: optimize patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.

• orthoses or prostheses fit: optimize patient outcomes related to human-device interface through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.

• orthoses or prostheses function: optimize patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

https://cdmrp.army.mil/funding/oporp

clinical research award – letter of intent due june 10, 2020

independent investigators at all academic levels (or equivalent).

• supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to service members, veterans, and other individuals with limb loss and/or limb impairment.
• supported research is intended to generate clinically useful evidence with potential to enhance and optimize patient outcomes.
• multidisciplinary collaboration among academics, industry, patient advocacy, the military services, the department of veterans affairs (va), and/or other federal government agencies is highly encouraged.
• applications submitted to the fy20 oporp cra must address one or more of the fy20 oporp focus areas.
• preclinical studies using animals are not allowed.
• clinical trials are not allowed.
• the fy20 cra offers two funding levels:

• funding level 1
• maximum funding of $350,000 for total costs (direct plus indirect costs).
• maximum period of performance is 2 years.
• funding level 2
• maximum funding of $2,000,000 for total costs (direct plus indirect costs).
• maximum period of performance is 4 years.

clinical trial award – letter of intent due june 10, 2020

independent investigators at all academic levels (or equivalent).

• supports implementation of clinical trials with the potential to have a significant impact on improving the health and well-being of service members, veterans, and other individuals living with limb loss and/or limb impairment.
• supports clinical trials that evaluate orthoses and/or prostheses using patient-centric outcomes for the purpose of generating clinically useful evidence to enhance and optimize patient outcomes.
• multidisciplinary collaborations among academia, industry, patient advocacy, the military services, va, and/or other federal government agencies is highly encouraged.
• applications submitted to the fy20 oporp cta must address one or more of the fy20 oporp focus areas.
• funding level 1 supports pilot clinical trials which are exploratory and involve limited human exposure with the potential to make significant advancement toward clinical translation. preliminary data are allowed but not required.
• funding level 2 supports clinical trials with the potential to make significant advancement toward clinical translation. preliminary data relevant to the proposed clinical trial are required.
• preclinical research is not allowed.
• the fy20 cta offers two funding levels:

• funding level 1
• funding level 2
• maximum period of performance is 4 years.

• maximum funding of $350,000 for total costs (direct plus indirect costs).
• maximum period of performance is 2 years.

• maximum funding of $4,000,000 for total costs (direct plus indirect costs).

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the oporp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

department of defense neurofibromatosis research program

funding opportunities for fiscal year 2020 (fy20)

the fy20 defense appropriations act is providing funding to the department of defense neurofibromatosis research program (nfrp) to support innovative, high-impact nf research.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy20 nfrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

areas of emphasis: the nfrp encourages applications that specifically address the critical needs of the nf community in one or more of the fy20 areas of emphasis.  not all areas of emphasis are applicable to each award mechanism offered by the fy20 nfrp.  if the proposed research project does not address one of the fy20 areas of emphasis, justification that the proposed research project addresses an important problem related to nf research and/or patient care should be provided. applications submitted to the fy20 nfrp must address one or more of the following areas of emphasis:

• biomarker discovery, utility, development, and validation
• non-tumor manifestations not limited to:

o  pain

o  cognitive manifestations

o  sleep

• heterogeneity of nf-related tumors
• novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
• preclinical efficacy studies
• target identification, drug discovery
• nutritional, environmental, and other modifiers of nf
• health services research

https://cdmrp.army.mil/funding/nfrp

clinical trial award – letter of intent due june 25, 2020

must be at or above the level of assistant professor (or equivalent)

• supports research with the potential to have a major impact on the treatment or management of neurofibromatosis (nf).
• funds phase 0, i, or ii clinical trials relevant to nf and/or schwannomatosis.  combinations of phases are permitted.
• must support a clinical trial and may not be used for preclinical research studies.
• the maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 in direct costs if requesting the qualified collaborator option)
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 4 years

exploration – hypothesis development award – letter of intent due june 25, 2020

investigators at all academic levels (or equivalent)

• supports the initial exploration of innovative, high-risk, high-gain concepts and potentially groundbreaking concepts in nf research.
• preliminary and/or published data is encouraged but not required.
• projects involving human subjects or human anatomical substances must be exempt under 32 cfr 219.104(d) or eligible for expedited review under 32 cfr 219.110 or 21 cfr 56.110.
• clinical trials not allowed.
• the maximum allowable funding for the entire period of performance is $100,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• the maximum period of performance is 2 years

new investigator award – letter of intent due june 25, 2020

must be either:

an independent investigator at or below the level of assistant professor (or equivalent) and must plan to commit at least 30% of his/her effort toward the proposed research project;

or

an established independent investigator in an area other than nf at or above the level of assistant professor seeking to transition into a career in nf research and must plan to commit at least 10% of his/her effort toward the proposed research project.

to be eligible, applicants may not have received more than $300,000 in direct costs for nf research as a principal investigator of one or more federally funded, non-mentored peer reviewed grants.

• supports the continued development of promising independent investigators and/or the transition of established investigators from other research fields into a career in nf research.
• prior experience in nf research is not required.
• preliminary and/or published data relevant to nf and the proposed data research project is required.
• clinical trials not allowed
  • the maximum allowable funding for the entire period of performance is $450,000 in direct costs.
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • the maximum period of performance is 3 years

early investigator research award – letter of intent due june 25, 2020

the investigator must:

be involved in a postdoctoral training or medical residency programs, and

possess at least 1 and up to 4 years of continuous postdoctoral research experience by the early investigator research award application submission deadline: and

possess a doctoral degree (i.e., ph.d, m.d./ph.d, d.o./ph.d) or a clinical doctoral degrees (i.e., m.d./d.o. or ph.d. in a clinical discipline) from an accredited organization or program.

• supports nf-focused research opportunities for individuals in the early stages of their careers.
• investigators must have a designated mentor who is an experienced nf researcher.
  • the maximum allowable funding for the entire period of performance is $200,000 in direct costs.
  • indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • the maximum period of performance is 2 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the nfrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the alzheimer’s drug discovery foundation (addf) and harrington discovery institute have partnered to form the addf-harrington scholar program. this program recognizes physicians or scientists across the us and canada, who are doing research to develop drugs to prevent, treat and cure alzheimer’s disease. the award provides funding and drug development support to help bridge the gap between basic discovery and the clinical realm.

up to three addf-harrington scholar awards are made each year through a competitive selection process.

the fy20 defense appropriation provides $15 million (m) to the department of defense autism research program (arp) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (asd).  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program’s research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

fy20 arp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

https://cdmrp.army.mil/funding/arp

clinical trial award – preapplication due april 28, 2020

investigators at or above the level of assistant professor (or equivalent), or

early-career investigator partnering principal investigator (pi) option: investigators at or above the level of assistant professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:

• must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
• is no more than 7 years from the receipt of a terminal degree

• has the freedom to commit at least 50% time to the project

supports research with the potential to have a major impact on the treatment and/or management of asd.

applications in the following areas are strongly encouraged:

• dissemination/implementation of clinically validated interventions
• behavioral, cognitive, and other non-pharmacological therapies for asd core symptoms or to alleviate co-occurring conditions.
• pharmacological, genetic, and other biological treatments for asd core symptoms or to alleviate co-occurring conditions.
• improve diagnosis and access to services across the life span
• interventions promoting success in key transitions to adulthood for individuals living with asd
• healthcare provider-focused training or tools to improve healthcare delivery for individuals with asd across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
• cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
• understanding heterogeneity in treatment response

preliminary data relevant to the proposed clinical trial are required.

pre-application is required; application submission is by invitation only.

early-career investigator partnering pi option supports the development of young investigators pursuing or wishing to pursue a career in asd clinical trial research.

the maximum allowable funding for the entire period of performance is $2,000,000 in direct costs (plus indirect costs).

maximum period of performance is 4 years.

early-career investigator partnering pi option:

the maximum allowable funding for the entire period of performance is $2,300,000 for direct costs (plus indirect costs).

maximum period of performance is 4 years.

clinical translational research award – preapplication due april 28, 2020

investigators at or above the level of assistant professor (or equivalent)

• supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of asd.
• applications in the following areas are strongly encouraged:

• dissemination/implementation of clinically validated interventions
• behavioral, cognitive, and other non-pharmacological therapies for asd core symptoms or to alleviate co-occurring conditions.
• pharmacological, genetic, and other biological treatments for asd core symptoms or to alleviate co-occurring conditions.
• improve diagnosis and access to services across the life span
• interventions promoting success in key transitions to adulthood for individuals living with asd
• healthcare provider-focused training or tools to improve healthcare delivery for individuals with asd across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
• cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
• understanding heterogeneity in treatment response
• pre-application is required; application submission is by invitation only.
• maximum period of performance is 3 years.

• preliminary data relevant to the proposed project are required.

• the maximum allowable funding for the entire period of performance is $600,000 in direct costs (plus indirect costs).

idea development award – preapplication due april 28, 2020

investigators at or above the level of assistant professor (or equivalent)

multiple pi option:   up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award. 

• supports the development of innovative, high-impact ideas that advance the understanding of asd and ultimately lead to improved outcomes.
• applications in the following areas are strongly encouraged:
  • test of implementation strategies to increases use of evidence-based practices
  • development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with asd across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
  • assessment of novel therapeutics using valid preclinical models
  • mechanisms of heterogeneous clinical expression of asd
  • environmental risk factors
  • improve diagnosis across the life span
  • factors promoting success in key transitions to independence for individuals living with asd
  • cultural and socioeconomic factors in treatment efficacy, delivery, and access to services
  • mechanisms underlying sex differences in asd diagnosis
  • mechanisms underlying conditions co-occurring with asd (e.g., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures)
  • factors impacting quality of life during geographic relocation, such as military permanent change of station
  • long-term treatment outcomes from previous clinical trials for asd core symptoms or to alleviate co-occurring conditions
• preliminary data are required.
• multiple pi option: up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award.
• pre-application is required; application submission is by invitation only.

• the maximum allowable funding for the entire period of performance is $550,000 in direct costs (plus indirect costs).

• maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the arp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk 
301-682-5507 
help@ebrap.org

description: fund canadian-led network(s) to plan and implement activities related to connecting and bridging partnerships, enabling global access of amr related tools and knowledge, facilitating data sharing and supporting capacity building leading to awareness and scientific innovation.
funding: $604k cihr-iii and cihr-ipph, over 3 years
deadline: april 2020 (full proposal)

the canadian cancer society (ccs) is issuing a special call for grant applications focused on rare and aggressive uterine cancers, with an emphasis on uterine carcinosarcoma in particular. as a result of a generous donation, there is funding available to support one meritorious application that will impact our understanding of uterine carcinosarcoma and other aggressive uterine cancers, particularly as it relates to the prevention, early detection, diagnosis, and/or treatment of these hard-to-treat cancers. 

eligible types of uterine cancer include:

•   uterine carcinosarcoma
•   serous carcinoma
•   uterine leiomyosarcoma
•   uterine clear cell carcinoma
•   endometrial stromal sarcoma (high-grade)
•   undifferentiated sarcomas